Aprotinin
Highest phase reached
Approved
Drug type
Protein
First approval year
1993
- First approval year
- 1993
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Aprotinin
- trasylol
- Trasylol
- aprotinin
- Aprotinin
- Aprotinin (bovine)
- Aprotinin (inhaled)
- Aprotinin (synthetic)
- APROTININ [EP IMPURITY]
- APROTININ [EP MONOGRAPH]
- aprotinin [INN]
- APROTININ [MART.]
- APROTININ [MI]
- APROTININ [ORANGE BOOK]
- APROTININ [USAN]
- APROTININ [USP MONOGRAPH]
- APROTININ [VANDF]
- Aprotinin [WHO-DD]
- aprotinin biosynthetic
- Aprotinin biosynthetic
- aprotinin bovine
- Aprotinin bovine
- aprotinin concentrated solution
- Aprotinin concentrated solution
- APROTININ CONCENTRATED SOLUTION [EP MONOGRAPH]
- aprotinin concentrated solution ep monograph
- aprotinin ep impurity
- aprotinin ep monograph
And 30 more, listed on the interactive page.
- ATC classification codes
- B02AB01
Sources for recorded values
- CAS registry numbers
- 9087-70-1
- ChEMBL ID
- CHEMBL1201619
- RxNorm IDs (RxCUI)
- 1056
- FDA ingredient codes (UNII)
- 04XPW8C0FL
- Applicant
- BAYER HLTHCARE
- Approval date
- 29 Dec 1993
- Application number
- BLA020304
- Patents
- 0
- Designations
- 2
- Earliest recorded loss of exclusivity
- 29 Dec 2000
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Withdrawn
- Pharmacology name
- aprotinin
- Type
- Peptide
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Binding
- Action type
- Binding
- Target
- plasminogen
- Gene symbol
- PLG
- Protein identifier
- P00747
- Median affinity
- 6.8
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Plasma kallikrein inhibitor
- Action type
- Inhibitor
- Target
- Plasma kallikrein
- Protein identifier
- P03952
- Mechanism
- Plasminogen inhibitor
- Action type
- Inhibitor
- Target
- Plasminogen
- Protein identifier
- P00747
- Mechanism
- Plasma kallikrein inhibitor
- Action type
- Inhibitor
- Target
- Plasma kallikrein
- Mechanism
- Plasminogen inhibitor
- Action type
- Inhibitor
- Target
- Plasminogen
- Condition
- Pancreatitis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000278
- Subject identifier
- D010195
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Hemorrhage
- Highest recorded phase
- 4
- Condition identifier
- MP:0001914
- Subject identifier
- D006470
- Condition identifier
- EFO_0000278
- Highest recorded phase
- 1
- Condition identifier
- HP_0001297
- Condition identifier
- MONDO_0002243
- Condition identifier
- MONDO_0002243
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006502
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006515
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006649
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0100096
- Condition identifier
- MP_0001914
- Condition identifier
- MP_0001914
- Highest recorded phase
- 4
Warnings
- Warning
- Withdrawn
- Description
- Increased mortality
- Year
- 2007
Open Targets warnings
- Warning
- Withdrawn
- Description
- Increased mortality
- Year
- 2007
- Country
- United States
- Condition
- dead
- Event
- anaphylactic reaction
- Reports
- 53
- Reporting signal score
- 95.1727
- Event
- anhedonia
- Reports
- 208
- Reporting signal score
- 1,230.32
- Event
- anxiety
- Reports
- 365
- Reporting signal score
- 1,115.06
- Event
- arterial thrombosis
- Reports
- 4
- Reporting signal score
- 9.53139
- Event
- asthenia
- Reports
- 3
- Reporting signal score
- 7.27345
- Event
- blood creatinine increased
- Reports
- 21
- Reporting signal score
- 18.9611
- Event
- blood pressure decreased
- Reports
- 17
- Reporting signal score
- 16.5701
- Event
- blood pressure systolic decreased
- Reports
- 5
- Reporting signal score
- 9.85848
- Event
- bronchospasm
- Reports
- 8
- Reporting signal score
- 9.68022
- Event
- cardiac arrest
- Reports
- 13
- Reporting signal score
- 14.5098
- Event
- cardiogenic shock
- Reports
- 7
- Reporting signal score
- 10.6101
- Event
- cerebrovascular accident
- Reports
- 95
- Reporting signal score
- 168.757
- Event
- coagulopathy
- Reports
- 7
- Reporting signal score
- 9.21521
- Event
- condition aggravated
- Reports
- 1
- Reporting signal score
- 8.98089
- Event
- depression
- Reports
- 147
- Reporting signal score
- 295.846
- Event
- dialysis
- Reports
- 9
- Reporting signal score
- 15.2143
- Event
- disability
- Reports
- 27
- Reporting signal score
- 92.3648
- Event
- dizziness
- Reports
- 1
- Reporting signal score
- 16.3517
- Event
- electrocardiogram st segment abnormal
- Reports
- 3
- Reporting signal score
- 9.06956
- Event
- electrocardiogram st segment elevation
- Reports
- 6
- Reporting signal score
- 12.9292
- Event
- embolic stroke
- Reports
- 6
- Reporting signal score
- 13.0084
- Event
- emotional disorder
- Reports
- 7
- Reporting signal score
- 10.1329
- Event
- emotional distress
- Reports
- 320
- Reporting signal score
- 1,624.7
- Event
- fall
- Reports
- 1
- Reporting signal score
- 10.927
- Event
- fear
- Reports
- 337
- Reporting signal score
- 1,851.37
And 38 more, listed on the interactive page.
- NCT00290836
- NCT00306150
- NCT00327379
- NCT00354900
- NCT00357851
- Allow at least 2 minutes for polymerization
- Apply as a thin layer by dripping or spraying
- Do not expose to temperatures above 37°C
- Do not microwave
- Use sufficient amount to cover application area
- Use within 4 hours after warming to 33-37°C
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Protein
- Sequence
- RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
Related records
Trials (234)
- "The Effect of Inhaled Nitroglycerin for COPD Patients
- A Clinical Study Evaluating Inhaled Aviptadil on COVID-19
- A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Efficacy Study
- A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Pharmacokinetic Study
- A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
- A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)
- A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device
- A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous Propofol
- A Prospective, Single-center, Open-label Clinical Study to Evaluate the Safety and Efficacy of Inhaled BMD003(CFTR mRNA) in Chinese Adult Patients With Cystic Fibrosis
- A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
- A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
- A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma
- A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors
- A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- A Study of Staccato Loxapine (ADASUVE®) for Inhalation
- A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung Disease
- A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
- A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.
In development for (2)
- Breast cancer Phase 1
- Pancreatitis Phase 1
Other linked conditions (2)
- COVID-19
- Hemorrhagic disease